Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.

Saved in:
Bibliographic Details
Title: Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.
Authors: DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Wang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lavu S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Chien K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Mill CP; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Su X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX., Fiskus W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Bhalla KN; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Source: Blood neoplasia [Blood Neoplasia] 2025 Jul 25; Vol. 2 (4), pp. 100145. Date of Electronic Publication: 2025 Jul 25 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2950-3280
DOI:10.1016/j.bneo.2025.100145